Home
>
ipos-overview
Proposed Symbol | BLUWU |
---|---|
Company Name | Blue Water Acquisition Corp. III |
Exchange | NASDAQ Global |
Share Price | $10.00 |
Employees | 2 (as of 06/11/2025) |
Status | Priced |
Shares Offered | 22,000,000 |
Offer amount | $220,000,000 |
Shares Over Alloted | |
Company Address | 15 E. PUTNUM AVENUE SUITE 363 GREENWICH CT 06830 |
Company Phone | 646-303-0737 |
Company Website | www.ategrity.com |
CEO | Joseph Hernandez |
State of Inc | |
Fiscal Year End | 12-31 |
Total Offering Expense | $750,000.00 |
Shareholder Shares Offered | |
Shares Outstanding | 28,120,000 |
Lockup Period (days) | 180 |
Lockup Expiration | 2025-12-08 00:00:00 |
Quiet Period Expiration | 2025-07-21 00:00:00 |
CIK | 0002050501 |
DealId | 1325924-113066 |
We are a blank check company incorporated on November 1, 2024 as a Cayman Islands exempted company with no material operations of our own and formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. We have not selected any business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. While we may pursue an acquisition opportunity in any business, industry, sector or geographical location, we intend to focus on high-potential companies in the biotechnology, healthcare and technology sectors. Our mission is to leverage our management team’s extensive expertise and deep industry connections to drive transformative advancements and generate substantial returns for our investors. Investment Focus We are strategically positioned to capitalize on the immense opportunities within the biotechnology, healthcare and technology sectors. With a seasoned team, extensive industry experience and a disciplined investment approach, we are committed to creating value for our investors while fostering the next generation of industry leaders. Biotechnology and Healthcare The biotechnology and healthcare sectors are experiencing rapid growth fueled by innovations in drug discovery, personalized medicine, medical devices and telemedicine. We intend to target companies that are leading the charge in developing groundbreaking therapies, diagnostic tools and health technology solutions. Key areas of focus include: . Pharmaceutical Development: We intend to seek investments in companies with promising drug pipelines aimed at addressing unmet medical needs. . Medical Devices: Our strategy includes supporting the development of advanced devices that enhance patient outcomes and streamline healthcare delivery. . Telemedicine: We aim to enhance healthcare accessibility through digital health platforms and remote monitoring solutions. . Health Tech Innovations: Our focus encompasses advancements in AI-driven diagnostics, wearable health technologies, and health data analytics. Technology The technology sector remains a critical driver of economic growth and innovation. Our investment strategy is centered on companies that are revolutionizing industries through advanced technological solutions. Key areas of interest include: . Artificial Intelligence and Machine Learning: We intend to invest in AI-driven companies that offer transformative solutions across multiple sectors. . Cloud Computing: Our focus includes businesses that provide scalable and efficient cloud infrastructure and services. . Cybersecurity: We prioritize investments in companies developing cutting-edge cybersecurity solutions to enhance digital security. . Enterprise Software Solutions: Our strategy supports software companies that enhance business efficiency, productivity and decision-making. --- Our executive offices are located at 15 E. Putnam Avenue, Suite 363, Greenwich, CT 06830, and our telephone number is (203) 489-2110.